Royal Bank of Canada cut its price target on Legend Biotech in a research report.
2 reports, 1 independent
Updated Aug 18
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Royal Bank of Canada cut its price target on Legend Biotech in a research report.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Legend Biotech
Biotech company
Nothing else this week.
-
Royal Bank of Canada
financial institution in Canada
Related events
- Legend Biotech and BioTech, both healthcare companies, are currently competing for investment.
- Royal Bank of Canada issued a price objective and Benzinga reported a target price reduction for Aardvark Therapeutics, Inc.
- Royal Bank of Canada reduced its target price for Tenet Healthcare.
- Royal Bank of Canada raised its target price for DCH.
- Financial firms, including RBC, TD Cowen, Leerink Partners, and Morgan Stanley, raised price targets and provided coverage for Vertex Pharmaceuticals.